| Mitogen‑activated protein kinase kinase 1 (MEK1, MAP2K1) is a dual‑specificity protein kinase in the Raf–MEK–ERK module of the MAPK signaling cascade, and phosphorylation at Thr286 defines a cell cycle‑regulated inhibitory state that modulates the strength and timing of ERK signaling in proliferating cells. The kinase contains an N‑terminal regulatory region with docking sites for Raf and ERK, an activation loop bearing Ser218 and Ser222 that control catalytic activation, and a C‑terminal segment that carries Thr286 and Thr292 alongside additional phospho‑acceptor residues, creating a platform for both positive and negative regulatory inputs. Raf‑dependent phosphorylation of Ser218/Ser222 and upstream growth factor or cytokine signals activate MEK1, which then phosphorylates ERK1/2 on threonine and tyrosine residues within their activation loops, driving downstream transcriptional and cytoskeletal programs that support proliferation, differentiation, and survival, while additional inputs from PAK1 at Ser298 facilitate efficient signal transfer from Raf to MEK1 and ERK. Cyclin‑dependent kinases such as Cdk1 and Cdk5 phosphorylate MEK1 at Thr286 and Thr292 during specific phases of the cell cycle, and this modification reduces MEK1 catalytic output toward ERK, thereby creating a negative feedback mechanism that limits ERK activity as cells progress through mitosis and prevents uncontrolled propagation of mitogenic signals. The phospho‑Thr286 form of MEK1 thus marks a pool of kinase that is engaged in feedback regulation rather than forward signal transmission, and detection of this isoform provides a readout of cell cycle–linked braking on the ERK pathway, which is relevant in tissues and tumor contexts where MAPK signaling and cell division are tightly coupled. Patterns of Thr286 phosphorylation vary with proliferative status and oncogenic context, and altered balance between activating loop phosphorylation and inhibitory Thr286/Thr292 phosphorylation influences ERK output, impacting gene expression programs that govern growth, apoptosis resistance, and tumor cell behavior. |
Lane 1: HeLa, Lane 2: HeLa (nocodazole, 100ng/ml, 24 h)
